BioCatalyst

Nemolizumab — catalyst calendar

3 verified catalyst event(s) referencing Nemolizumab, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08-31
in 2mo
ESTIMATED
 READOUT
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Derm
Phase 3 · Moderate-to-Severe Atopic Dermatitis
 Galderma R&D Nemolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-09 (month)
in 2mo
ESTIMATED
 READOUT
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemoli
Phase 2 · Chronic Pruritus of Unknown Origin
 Galderma R&D nemolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-10-26
in 4mo
ESTIMATED
 READOUT
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodulari
Phase 3 · Prurigo Nodularis
 Galderma R&D Nemolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.